Chemclin Diagnostics Co. Ltd. A
Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such a… Read more
Chemclin Diagnostics Co. Ltd. A - Asset Resilience Ratio
Chemclin Diagnostics Co. Ltd. A (688468) has an Asset Resilience Ratio of 12.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Chemclin Diagnostics Co. Ltd. A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Chemclin Diagnostics Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥215.00 Million | 12.14% |
| Total Liquid Assets | CN¥215.00 Million | 12.14% |
Asset Resilience Insights
- Moderate Liquidity: Chemclin Diagnostics Co. Ltd. A has 12.14% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Chemclin Diagnostics Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Chemclin Diagnostics Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
|
Bionet
TWO:1784 |
Diagnostics & Research | 38.62% |
|
Cytogen Inc
KQ:217330 |
Diagnostics & Research | 39.93% |
Annual Asset Resilience Ratio for Chemclin Diagnostics Co. Ltd. A (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Chemclin Diagnostics Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 27.78% | CN¥509.00 Million | CN¥1.83 Billion | +1.97pp |
| 2023-12-31 | 25.82% | CN¥470.00 Million | CN¥1.82 Billion | -14.59pp |
| 2022-12-31 | 40.41% | CN¥643.00 Million | CN¥1.59 Billion | -2.43pp |
| 2021-12-31 | 42.84% | CN¥613.00 Million | CN¥1.43 Billion | +10.21pp |
| 2020-12-31 | 32.63% | CN¥328.57 Million | CN¥1.01 Billion | -15.68pp |
| 2019-12-31 | 48.32% | CN¥480.00 Million | CN¥993.39 Million | -- |